NewAmsterdam Pharma Company NV (NASDAQ:NAMS) price on Friday, June 13, fall -3.90% below its previous day’s close as a downside momentum from buyers pushed the stock’s value to $20.21.
A look at the stock’s price movement, the close in the last trading session was $21.03. Turning to its 52-week performance, $27.29 and $14.06 were the 52-week high and 52-week low respectively. Overall, NAMS moved 7.79% over the past month.
NewAmsterdam Pharma Company NV’s market cap currently stands at around $2.27 billion, with investors looking forward to this quarter’s earnings report slated for in July.
1 analyst(s) have given their forecast ratings for the stock on a scale of 1.00-5.00 for a strong buy to strong sell recommendation. A total of 0 analyst(s) rate the stock as a Hold, 1 recommend NAMS as a Buy and 0 give it an Overweight rating. Meanwhile, 0 analyst(s) rate the stock as Underweight and 0 say it is a Sell. As such, the average rating for the stock is Buy which could provide an opportunity for investors keen on increasing their holdings of the company’s stock.
NAMS’s current price about 5.78% and 11.07% off the 20-day and 50-day simple moving averages respectively. The Relative Strength Index (RSI, 14) currently prints 55.84, while 7-day volatility ratio is 6.49% and 3.51% in the 30-day chart. Further, NewAmsterdam Pharma Company NV (NAMS) has a beta value of -0.01, and an average true range (ATR) of 1.32. Analysts have given the company’s stock an average 52-week price target of $44.5, forecast between a low of $41 and high of $48. Looking at the price targets, the low is -102.87% off current price level while to achieve the yearly target high, price needs to move -137.51%. Nonetheless, investors will most likely welcome a -120.19% jump to $44.5 which is the analysts’ median price.
If we refocus on NewAmsterdam Pharma Company NV (NASDAQ:NAMS), historical trading data shows that trading volumes averaged 914.71K over the past 3 months. The company’s latest data on shares outstanding shows there are 112.17 million shares.
The 44.59% of NewAmsterdam Pharma Company NV’s shares are in the hands of company insiders while institutional holders own 57.42% of the company’s shares. Current price change has pushed the stock -21.36% YTD, which shows the potential for further growth is there. It is this reason that could see investor optimism for the NAMS stock continues to rise going into the next quarter.
